- Home
- KEP vs BBIO Comparison
KEP vs BBIO Comparison
Compare KEP & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KEP | BBIO |
|---|---|---|
| Founded | 1961 | 2015 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 15.9B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KEP | BBIO |
|---|---|---|
| Price | $11.70 | $80.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 25 |
| Target Price | N/A | ★ $86.33 |
| AVG Volume (30 Days) | 1.0M | ★ 2.0M |
| Earning Date | 06-16-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $3.18 | $89.45 |
| Revenue Next Year | $2.21 | $73.78 |
| P/E Ratio | $4.54 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $11.25 | $46.81 |
| 52 Week High | $23.41 | $93.42 |
Technical Indicators
Market Signals| Indicator | KEP | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 47.43 |
| Support Level | $11.29 | $78.90 |
| Resistance Level | $12.62 | $85.34 |
| Average True Range (ATR) | 0.28 | 2.87 |
| MACD | -0.02 | -0.59 |
| Stochastic Oscillator | 26.30 | 16.02 |
Price Performance
Historical ComparisonAbout KEP Korea Electric Power Corporation
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment. Geographically, it derives maximum revenue from Domestic operations.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.